Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC18 (Telitacicept) in Generalized Myasthenia Gravis – Phase II China Study
CTR20200317Phase 2Completed
- Sponsor
- Rongchang Pharmaceuticals
- Start
- Mar 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in myasthenia gravis (MG), sponsored by Rongchang Pharmaceuticals. Started Mar 2020; status: completed.
02
Drugs
telitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20200317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200317.